Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of “Moderate Buy” from Analysts

Sutro Biopharma, Inc. (NASDAQ:STRO) has been assigned a consensus rating of “Moderate Buy” from the twelve ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $52.4444.

A number of research firms have issued reports on STRO. Truist Financial initiated coverage on Sutro Biopharma in a report on Thursday, June 11th. They set a “buy” rating and a $50.00 target price for the company. Lifesci Capital raised Sutro Biopharma to a “strong-buy” rating in a research report on Friday, May 1st. Citizens Jmp increased their price objective on Sutro Biopharma from $35.00 to $41.00 and gave the stock a “market outperform” rating in a report on Thursday, April 23rd. Leerink Partners set a $43.00 price objective on Sutro Biopharma and gave the stock an “outperform” rating in a report on Friday, May 15th. Finally, HC Wainwright lifted their target price on Sutro Biopharma from $28.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, May 15th.

Institutional Trading of Sutro Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Velan Capital Investment Management LP lifted its position in shares of Sutro Biopharma by 2.0% in the third quarter. Velan Capital Investment Management LP now owns 3,120,000 shares of the company’s stock worth $2,709,000 after purchasing an additional 60,000 shares in the last quarter. UBS Group AG grew its position in Sutro Biopharma by 14.0% in the third quarter. UBS Group AG now owns 1,845,839 shares of the company’s stock valued at $1,602,000 after purchasing an additional 226,955 shares in the last quarter. AQR Capital Management LLC grew its position in Sutro Biopharma by 1,052.8% in the first quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock valued at $859,000 after purchasing an additional 1,206,330 shares in the last quarter. Affinity Asset Advisors LLC increased its stake in Sutro Biopharma by 42.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,069,519 shares of the company’s stock valued at $26,642,000 after buying an additional 321,137 shares during the last quarter. Finally, Orbimed Advisors LLC acquired a new stake in Sutro Biopharma in the 1st quarter valued at $19,956,000. 96.99% of the stock is currently owned by institutional investors and hedge funds.

Sutro Biopharma Stock Up 0.6%

Sutro Biopharma stock opened at $30.43 on Friday. The stock has a market capitalization of $504.23 million, a PE ratio of -2.76 and a beta of 1.51. Sutro Biopharma has a twelve month low of $7.15 and a twelve month high of $43.85. The company has a 50 day moving average of $31.65 and a 200-day moving average of $23.09.

Sutro Biopharma (NASDAQ:STRO) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($2.94) EPS for the quarter, missing analysts’ consensus estimates of ($2.74) by ($0.20). The company had revenue of $14.52 million for the quarter, compared to analyst estimates of $8.89 million. Equities analysts anticipate that Sutro Biopharma will post -9 EPS for the current fiscal year.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.